SCHEMBL17455933

SCHEMBL17455933

O=S(=O)(C1CC1)N1CCC(Oc2cccnc2-c2ccncc2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 3/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ IKBKB O14920 2/20 0.37
▸ CHUK O15111 1/20 0.37
▸ NAMPT P43490 1/20 0.36
▸ CACNB4 O00305 1/20 0.36
▸ CACNA1A O00555 1/20 0.36
▸ CACNA1G O43497 1/20 0.36
▸ CACNG3 O60359 1/20 0.36
▸ CACNA1F O60840 1/20 0.36
▸ CACNA1H O95180 1/20 0.36
▸ CACNB3 P54284 1/20 0.36
▸ CACNA2D1 P54289 1/20 0.36
▸ CACNG7 P62955 1/20 0.36
▸ CACNA1B Q00975 1/20 0.36
▸ CACNA1D Q01668 1/20 0.36
▸ CACNB1 Q02641 1/20 0.36
▸ CACNG1 Q06432 1/20 0.36
▸ CACNB2 Q08289 1/20 0.36
▸ CACNA1S Q13698 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17456033 0.88 IKBKB (0.47) CYP11B1CYP11B2IKBKBCHUKNAMPT
SCHEMBL17455913 0.86 LMNA (0.39) CYP11B1CYP11B2IKBKBCHUKPIK3CD
SCHEMBL17456034 0.86 CACNB4 (0.38) CYP11B1CYP11B2IKBKBCHUKCACNB4
SCHEMBL17455979 0.86 MCHR1 (0.43) CYP11B1CYP11B2IKBKBCHUKNAMPT
SCHEMBL17455936 0.86 CACNB4 (0.39) CYP11B1CYP11B2IKBKBCHUKNAMPT
SCHEMBL17455917 0.86 CYP1A2 (0.47) CYP11B1CYP11B2IKBKBCHUKRBP4
SCHEMBL17455995 0.86 GPR119 (0.36) IKBKBCHUKNAMPTGPR119MCHR1
SCHEMBL17455962 0.85 PDE10A (0.45) CYP11B1NAMPTPIK3CDPIK3CACYP17A1
SCHEMBL17455952 0.84 KDM4E (0.47) MCHR1HTR2CKCNH2
SCHEMBL17456044 0.84 MCHR1 (0.44) NAMPTGPR119MCHR1HTR2CKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 CYP11B1 88/4885CYP11B2 82/4885IKBKB 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback